Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients
Background - The combination of intermediate-dose cytarabine plus mitoxantrone (IMA) can induce high complete remission rates with acceptable toxicity in elderly patients with acute myeloid leukemia (AML). We present the final results of a randomized-controlled trial comparing IMA with the standard...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2018
|
| In: |
Annals of oncology
Year: 2018, Jahrgang: 29, Heft: 4, Pages: 973-978 |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdy030 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1093/annonc/mdy030 Verlag, lizenzpflichtig, Volltext: http://www.sciencedirect.com/science/article/pii/S0923753419454756 
|
| Verfasserangaben: | C. Röllig, M. Kramer, M. Gabrecht, M. Hänel, R. Herbst, U. Kaiser, N. Schmitz, J. Kullmer, S. Fetscher, H. Link, L. Mantovani-Löffler, U. Krümpelmann, T. Neuhaus, F. Heits, H. Einsele, B. Ritter, M. Bornhäuser, J. Schetelig, C. Thiede, B. Mohr, M. Schaich, U. Platzbecker, K. Schäfer-Eckart, A. Krämer, W.E. Berdel, H. Serve, G. Ehninger & U.S. Schuler, for the Study Alliance Leukemia (SAL) |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1694664902 | ||
| 003 | DE-627 | ||
| 005 | 20220818042221.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200416s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/annonc/mdy030 |2 doi | |
| 035 | |a (DE-627)1694664902 | ||
| 035 | |a (DE-599)KXP1694664902 | ||
| 035 | |a (OCoLC)1341315087 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Röllig, Christoph |d 1971- |e VerfasserIn |0 (DE-588)122493168 |0 (DE-627)705929116 |0 (DE-576)293296049 |4 aut | |
| 245 | 1 | 0 | |a Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients |c C. Röllig, M. Kramer, M. Gabrecht, M. Hänel, R. Herbst, U. Kaiser, N. Schmitz, J. Kullmer, S. Fetscher, H. Link, L. Mantovani-Löffler, U. Krümpelmann, T. Neuhaus, F. Heits, H. Einsele, B. Ritter, M. Bornhäuser, J. Schetelig, C. Thiede, B. Mohr, M. Schaich, U. Platzbecker, K. Schäfer-Eckart, A. Krämer, W.E. Berdel, H. Serve, G. Ehninger & U.S. Schuler, for the Study Alliance Leukemia (SAL) |
| 264 | 1 | |c 2018 | |
| 300 | |a 6 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Elektronische Reproduktion der Druckausgabe | ||
| 500 | |a Available online 7 January 2020 | ||
| 500 | |a Gesehen am 16.04.2020 | ||
| 520 | |a Background - The combination of intermediate-dose cytarabine plus mitoxantrone (IMA) can induce high complete remission rates with acceptable toxicity in elderly patients with acute myeloid leukemia (AML). We present the final results of a randomized-controlled trial comparing IMA with the standard 7+3 induction regimen consisting of continuous infusion cytarabine plus daunorubicin (DA). - Patients and methods - Patients with newly diagnosed AML>60years were randomized to receive either intermediate-dose cytarabine (1000mg/m2 twice daily on days 1, 3, 5, 7) plus mitoxantrone (10mg/m2 days 1-3) (IMA) or standard induction therapy with cytarabine (100mg/m2 continuously days 1-7) plus daunorubicin (45mg/m2 days 3-5) (DA). Patients in complete remission after DA received intermediate-dose cytarabine plus amsacrine as consolidation treatment, whereas patients after IMA were consolidated with standard-dose cytarabine plus mitoxantrone. - Results - Between February 2005 and October 2009, 485 patients were randomized; 241 for treatment arm DA and 244 for IMA; 76% of patients were >65years. The complete response rate after DA was 39% [95% confidence interval (95% CI): 33-45] versus 55% (95% CI: 49-61) after IMA (odds ratio 1.89, P=0.001). The 6-week early-death rate was 14% in both arms. Relapse-free survival curves were superimposable in the first year, but separated afterwards, resulting in 3-year relapse-free survival rates of 29% versus 14% in the DA versus IMA arms, respectively (P=0.042). The median overall survival was 10months in both arms (P=0.513). - Conclusion - The dose escalation of cytarabine in induction therapy lead to improved remission rates in the elderly AML patients. This did not translate into a survival advantage, most likely due to differences in consolidation treatment. Thus, effective consolidation strategies need to be further explored. In combination with an effective consolidation strategy, the use of intermediate-dose cytarabine in induction may improve curative treatment for elderly AML patients. | ||
| 650 | 4 | |a acute myeloid leukemia | |
| 650 | 4 | |a cytarabine dose | |
| 650 | 4 | |a elderly | |
| 700 | 1 | |a Krämer, Alwin |e VerfasserIn |0 (DE-588)1067780025 |0 (DE-627)819183431 |0 (DE-576)426900820 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology |d Amsterdam [u.a.] : Elsevier, 1990 |g 29(2018), 4, Seite 973-978 |h Online-Ressource |w (DE-627)320428796 |w (DE-600)2003498-2 |w (DE-576)098134345 |x 1569-8041 |7 nnas |a Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients |
| 773 | 1 | 8 | |g volume:29 |g year:2018 |g number:4 |g pages:973-978 |g extent:6 |a Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients |
| 856 | 4 | 0 | |u https://doi.org/10.1093/annonc/mdy030 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S0923753419454756 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200416 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 1067780025 |a Krämer, Alwin |m 1067780025:Krämer, Alwin |d 910000 |d 910100 |e 910000PK1067780025 |e 910100PK1067780025 |k 0/910000/ |k 1/910000/910100/ |p 24 | ||
| 999 | |a KXP-PPN1694664902 |e 3624024221 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["C. Röllig, M. Kramer, M. Gabrecht, M. Hänel, R. Herbst, U. Kaiser, N. Schmitz, J. Kullmer, S. Fetscher, H. Link, L. Mantovani-Löffler, U. Krümpelmann, T. Neuhaus, F. Heits, H. Einsele, B. Ritter, M. Bornhäuser, J. Schetelig, C. Thiede, B. Mohr, M. Schaich, U. Platzbecker, K. Schäfer-Eckart, A. Krämer, W.E. Berdel, H. Serve, G. Ehninger & U.S. Schuler, for the Study Alliance Leukemia (SAL)"]},"person":[{"display":"Röllig, Christoph","role":"aut","given":"Christoph","family":"Röllig","roleDisplay":"VerfasserIn"},{"family":"Krämer","roleDisplay":"VerfasserIn","given":"Alwin","display":"Krämer, Alwin","role":"aut"}],"physDesc":[{"extent":"6 S."}],"relHost":[{"pubHistory":["1.1990 -"],"corporate":[{"roleDisplay":"Herausgebendes Organ","display":"European Society for Medical Oncology","role":"isb"}],"recId":"320428796","part":{"pages":"973-978","year":"2018","extent":"6","volume":"29","issue":"4","text":"29(2018), 4, Seite 973-978"},"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"publisher":"Elsevier ; Kluwer ; Oxford Univ. Press","publisherPlace":"Amsterdam [u.a.] ; Dordrecht [u.a.] ; Oxford","dateIssuedKey":"1990","dateIssuedDisp":"1990-"}],"id":{"issn":["1569-8041"],"eki":["320428796"],"zdb":["2003498-2"]},"title":[{"subtitle":"official journal of the European Society for Medical Oncology","title_sort":"Annals of oncology","title":"Annals of oncology"}],"disp":"Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patientsAnnals of oncology","note":["Gesehen am 12.11.20","Ungezählte Beil.: Supplement"]}],"origin":[{"dateIssuedKey":"2018","dateIssuedDisp":"2018"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"recId":"1694664902","id":{"eki":["1694664902"],"doi":["10.1093/annonc/mdy030"]},"title":[{"title":"Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients","title_sort":"Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients"}],"note":["Elektronische Reproduktion der Druckausgabe","Available online 7 January 2020","Gesehen am 16.04.2020"]} | ||
| SRT | |a ROELLIGCHRINTERMEDIA2018 | ||